首页 > 最新文献

Journal of clinical trials and regulations最新文献

英文 中文
Genesis of Clinical Trial Failure: A Review 临床试验失败的原因:回顾
Pub Date : 2023-12-08 DOI: 10.46610/jctr.2023.v05i02.005
S. Chaudhry, Abhijit Trailokya
Clinical Trials are often labelled as failure or negative when the anticipated results are not observed. The negative results can be due to multiple factors such as primary and secondary endpoints not being met higher incidence of adverse reactions, and sluggish recruitment of trial subjects due to stringent inclusion and exclusion criteria, higher dropout rates due to changed biochemical parameters such as raised liver or hepatic enzymes. Trial Failures are reported globally but within developing countries, the reports are meagre. Inclusion in trials imposes a financial burden on patients and hence dropout rates proportionately increase. Recruitment of patients is often better in open trials as compared to blind studies as drug awareness imposes better confidence in the recruited subjects. The oncology trials that use biomarkers in patient selection have higher overall success probabilities than trials without biomarkers. Complexities in drug development and the inherent uncertainties in medical research also play an important role in a high rate of clinical trial failures.
当临床试验没有达到预期结果时,通常会被称为失败或负面结果。负面结果可能由多种因素造成,如主要和次要终点未达到,不良反应发生率较高,严格的纳入和排除标准导致受试者招募缓慢,生化指标变化(如肝酶或肝酶升高)导致辍学率较高。全球都有试验失败的报告,但发展中国家的报告很少。纳入试验会给患者带来经济负担,因此辍学率也会相应增加。与盲法研究相比,公开试验通常能更好地招募患者,因为对药物的认识能增强被招募者的信心。与不使用生物标志物的试验相比,使用生物标志物选择患者的肿瘤试验的总体成功概率更高。药物开发的复杂性和医学研究固有的不确定性也是导致临床试验失败率高的重要原因。
{"title":"Genesis of Clinical Trial Failure: A Review","authors":"S. Chaudhry, Abhijit Trailokya","doi":"10.46610/jctr.2023.v05i02.005","DOIUrl":"https://doi.org/10.46610/jctr.2023.v05i02.005","url":null,"abstract":"Clinical Trials are often labelled as failure or negative when the anticipated results are not observed. The negative results can be due to multiple factors such as primary and secondary endpoints not being met higher incidence of adverse reactions, and sluggish recruitment of trial subjects due to stringent inclusion and exclusion criteria, higher dropout rates due to changed biochemical parameters such as raised liver or hepatic enzymes. Trial Failures are reported globally but within developing countries, the reports are meagre. Inclusion in trials imposes a financial burden on patients and hence dropout rates proportionately increase. Recruitment of patients is often better in open trials as compared to blind studies as drug awareness imposes better confidence in the recruited subjects. The oncology trials that use biomarkers in patient selection have higher overall success probabilities than trials without biomarkers. Complexities in drug development and the inherent uncertainties in medical research also play an important role in a high rate of clinical trial failures.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139011727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medico-Legal Cases: An Overview 医学法律案例:概述
Pub Date : 2023-09-13 DOI: 10.46610/jctr.2023.v05i02.002
Gurmeet Singh Sarla
A Medico-Legal Case can be defined as a case of injury or ailment in which investigations by the law-enforcing agencies are essential to fix the responsibility regarding the causation of the injury or ailment. Once the attending doctor decides to treat the case as Medico Legal Case, immediately he is required to inform the jurisdictional police as provided under Section 39 of Criminal Procedure Code, failure to do so, may result in a prosecution under Sections 176 or 202 of Indian Penal Code. Based on the report, police visits the patient to verify details mentioned in Medico-Legal Case. If there is subsequent death of patient or if the relatives wish to take a legal action against the offender, then based on the Medico-Legal Report, a First Information Report is registered under the relevant Indian Penal Code section. Medical practitioners share the responsibility of action against crime by supporting the justice system. The best way for a medical practitioner to achieve this is by proper examination of victims and/or perpetrators, and completing the legal documents meticulously. Medico-legal documentation is more than the compilation of a medico-legal report. Inappropriate completion of medico-legal documentation may necessitate the practitioner having to explain the documentation to make it understandable to the court.
医疗-法律案件可以定义为受伤或疾病的案件,其中执法机构的调查对于确定造成受伤或疾病的原因的责任至关重要。一旦主治医生决定将案件作为医学法律案件处理,他必须根据《刑事诉讼法》第39条的规定立即通知管辖警察,否则可能会根据《印度刑法》第176或202条受到起诉。根据报告,警察对病人进行了探视,以核实《医学法律案件》中提到的细节。如果病人随后死亡,或亲属希望对罪犯采取法律行动,则根据《法医报告》,根据《印度刑法》相关章节登记第一份信息报告。医生通过支持司法系统分担打击犯罪的责任。医生要做到这一点,最好的办法是对受害者和/或犯罪者进行适当的检查,并认真填写法律文件。医疗法律文件不仅仅是编纂一份医疗法律报告。医疗法律文件的不适当填写可能使执业医师必须对文件进行解释,使法院能够理解。
{"title":"Medico-Legal Cases: An Overview","authors":"Gurmeet Singh Sarla","doi":"10.46610/jctr.2023.v05i02.002","DOIUrl":"https://doi.org/10.46610/jctr.2023.v05i02.002","url":null,"abstract":"A Medico-Legal Case can be defined as a case of injury or ailment in which investigations by the law-enforcing agencies are essential to fix the responsibility regarding the causation of the injury or ailment. Once the attending doctor decides to treat the case as Medico Legal Case, immediately he is required to inform the jurisdictional police as provided under Section 39 of Criminal Procedure Code, failure to do so, may result in a prosecution under Sections 176 or 202 of Indian Penal Code. Based on the report, police visits the patient to verify details mentioned in Medico-Legal Case. If there is subsequent death of patient or if the relatives wish to take a legal action against the offender, then based on the Medico-Legal Report, a First Information Report is registered under the relevant Indian Penal Code section. Medical practitioners share the responsibility of action against crime by supporting the justice system. The best way for a medical practitioner to achieve this is by proper examination of victims and/or perpetrators, and completing the legal documents meticulously. Medico-legal documentation is more than the compilation of a medico-legal report. Inappropriate completion of medico-legal documentation may necessitate the practitioner having to explain the documentation to make it understandable to the court.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135740764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Silico Exploration of Dietary Polyphenol, Bisdemethoxycurcumin as a Potential CXCL12 Inhibitor in Breast Cancer Treatment 膳食多酚双去甲氧基姜黄素作为乳腺癌治疗中潜在的CXCL12抑制剂的硅研究
Pub Date : 2023-07-31 DOI: 10.46610/jctr.2023.v05i02.001
A. Mishra
Breast cancer stands as one of the most prevalent malignancies in women worldwide. The World Health Organization reported 2.3 million new cases and 685,000 fatalities due to breast cancer in 2020. In India alone, 162,468 new diagnoses and 87,090 deaths were recorded in 2018. CXCL12, also known as stromal cell-derived factor 1 (SDF-1), plays a significant role in tumor progression and metastasis in breast cancer, rendering it a promising target for intervention. Curcumin and its derivatives are known to inhibit breast cancer and enhance the efficacy of chemotherapeutic drugs. This study explores the potential of Bisdemethoxycurcumin, a synthesized derivative of curcumin, as a CXCL12 inhibitor in breast cancer. Our in-silico screening of Bisdemethoxycurcumin demonstrated a strong binding affinity to CXCL12, surpassing that of the reference compound, Plerixafor. We also compared our lead molecule with the reference compound (Plerixafor). Conversely, we observe that Bisdemethoxycurcumin shows a good binding affinity with the target protein and shows a strong bond interaction, particularly H-bond interaction in molecular docking and MD simulation studies both. Our findings identify Bisdemethoxycurcumin as a lead compound for future studies, necessitating validation through in vitro and in vivo investigations.
癌症是全世界女性最常见的恶性肿瘤之一。世界卫生组织报告,2020年癌症新增230万例,死亡68.5万例。仅在印度,2018年就记录了162468例新确诊病例和87090例死亡病例。CXCL12,也被称为基质细胞衍生因子1(SDF-1),在癌症的肿瘤进展和转移中发挥着重要作用,使其成为一个有前途的干预靶点。众所周知,姜黄素及其衍生物可以抑制癌症并提高化疗药物的疗效。本研究探讨了双去甲氧基姜黄素(一种合成的姜黄素衍生物)在癌症中作为CXCL12抑制剂的潜力。我们对双去甲氧基姜黄素的计算机筛选显示出对CXCL12的强结合亲和力,超过了参考化合物Plerixafor的结合亲和力。我们还将我们的先导分子与参考化合物(Plerixafor)进行了比较。相反,我们观察到双去甲氧基姜黄素与靶蛋白表现出良好的结合亲和力,并表现出强烈的键相互作用,特别是在分子对接和MD模拟研究中的氢键相互作用。我们的研究结果确定双去甲氧基姜黄素是未来研究的先导化合物,需要通过体外和体内研究进行验证。
{"title":"In Silico Exploration of Dietary Polyphenol, Bisdemethoxycurcumin as a Potential CXCL12 Inhibitor in Breast Cancer Treatment","authors":"A. Mishra","doi":"10.46610/jctr.2023.v05i02.001","DOIUrl":"https://doi.org/10.46610/jctr.2023.v05i02.001","url":null,"abstract":"Breast cancer stands as one of the most prevalent malignancies in women worldwide. The World Health Organization reported 2.3 million new cases and 685,000 fatalities due to breast cancer in 2020. In India alone, 162,468 new diagnoses and 87,090 deaths were recorded in 2018. CXCL12, also known as stromal cell-derived factor 1 (SDF-1), plays a significant role in tumor progression and metastasis in breast cancer, rendering it a promising target for intervention. Curcumin and its derivatives are known to inhibit breast cancer and enhance the efficacy of chemotherapeutic drugs. This study explores the potential of Bisdemethoxycurcumin, a synthesized derivative of curcumin, as a CXCL12 inhibitor in breast cancer. Our in-silico screening of Bisdemethoxycurcumin demonstrated a strong binding affinity to CXCL12, surpassing that of the reference compound, Plerixafor. We also compared our lead molecule with the reference compound (Plerixafor). Conversely, we observe that Bisdemethoxycurcumin shows a good binding affinity with the target protein and shows a strong bond interaction, particularly H-bond interaction in molecular docking and MD simulation studies both. Our findings identify Bisdemethoxycurcumin as a lead compound for future studies, necessitating validation through in vitro and in vivo investigations.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43186859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gel of Betel (Areca Catechu Linn.) Nut Ethanol Extract Activity Test as Cuts Healing against Diabetic Rabbits (Oryctolagus cuniculus) 槟榔凝胶对糖尿病兔切口愈合的乙醇提取物活性试验
Pub Date : 2023-05-17 DOI: 10.46610/jctr.2023.v05i01.004
E. Gunawan, M. Silvia, Nur Fadilah Bakri
Background: Areca nut (Areca catechu Linn.) contains the main components in the form of tannins, flavonoids, alkaloids, and saponins. People usually use the young betel nut as cuts medicine by mashing it and applying it directly to the cuts cut area or by boiling the betel nut and the boiled water is used to clean cuts and other skin infections. Objective: The purpose of this study was to determine the effect of giving betel nut (Areca catechu Linn.) ethanol extract gel and to determine the most effective concentration of cuts healing in diabetic rabbits (Oryctolagus cuniculus). Method: This study used 6 treatment groups, namely the group that was given a gel with an extract concentration of 1%, 3%, and 5%, a group that was given conventional preparations as a positive control, a group that was given a gel base as a negative control, and a group that was not given the test substance. The rabbit's back area was anesthetized with 2% lidocaine subcutaneously and a 2 cm long incision was made with a depth of 1.5 mm using a scalpel. The data obtained were the percentage of cuts healing in diabetic rabbits which were analyzed using One-way ANOVA. Results: The results showed that the percentage of cuts healing was 100% healed on gel treatment with 1% areca nut ethanol extract on the 11th day, gel with 3% betel nut ethanol extract on the 11th day, and gel with 5% betel nut ethanol extract on the 10th day. The results of One-way ANOVA statistical analysis showed a significant difference in the cuts healing effect of diabetic rabbits in each treatment with a value of p = 0.000 (p <0.05). Conclusion: The results of the study concluded that areca nut has activity in cuts healing in diabetic rabbits which was formulated in the form of a gel with an extract concentration of 5%.
背景:槟榔(Areca catechu Linn.)主要成分为单宁、黄酮、生物碱和皂苷。人们通常用年轻的槟榔作为切块药,将其捣碎并直接涂抹在切块区域,或者将槟榔煮沸,然后用开水清洗切块和其他皮肤感染。目的:研究槟榔乙醇提取物凝胶对糖尿病兔(Oryctolagus cuniculus)切口愈合的影响,并确定其最有效浓度。方法:本研究使用了6个治疗组,即给予提取物浓度为1%、3%和5%的凝胶的组,给予常规制剂作为阳性对照的组,给凝胶基质作为阴性对照的组和未给予受试物质的组。兔背部用2%利多卡因皮下麻醉,并用手术刀切开2cm长、深度1.5mm的切口。获得的数据是糖尿病兔伤口愈合的百分比,使用单向方差分析进行分析。结果:1%槟榔乙醇提取物凝胶治疗11天切口愈合率达100%,3%槟榔乙醇提取物胶凝治疗11天,5%槟榔乙醇提取物冻凝治疗10天。单因素方差分析的结果显示,糖尿病兔每次治疗的切口愈合效果有显著差异,其值为p=0.000(p<0.05)。结论:槟榔以5%提取物浓度的凝胶形式配制,具有糖尿病兔切口愈合活性。
{"title":"Gel of Betel (Areca Catechu Linn.) Nut Ethanol Extract Activity Test as Cuts Healing against Diabetic Rabbits (Oryctolagus cuniculus)","authors":"E. Gunawan, M. Silvia, Nur Fadilah Bakri","doi":"10.46610/jctr.2023.v05i01.004","DOIUrl":"https://doi.org/10.46610/jctr.2023.v05i01.004","url":null,"abstract":"Background: Areca nut (Areca catechu Linn.) contains the main components in the form of tannins, flavonoids, alkaloids, and saponins. People usually use the young betel nut as cuts medicine by mashing it and applying it directly to the cuts cut area or by boiling the betel nut and the boiled water is used to clean cuts and other skin infections. Objective: The purpose of this study was to determine the effect of giving betel nut (Areca catechu Linn.) ethanol extract gel and to determine the most effective concentration of cuts healing in diabetic rabbits (Oryctolagus cuniculus). Method: This study used 6 treatment groups, namely the group that was given a gel with an extract concentration of 1%, 3%, and 5%, a group that was given conventional preparations as a positive control, a group that was given a gel base as a negative control, and a group that was not given the test substance. The rabbit's back area was anesthetized with 2% lidocaine subcutaneously and a 2 cm long incision was made with a depth of 1.5 mm using a scalpel. The data obtained were the percentage of cuts healing in diabetic rabbits which were analyzed using One-way ANOVA. Results: The results showed that the percentage of cuts healing was 100% healed on gel treatment with 1% areca nut ethanol extract on the 11th day, gel with 3% betel nut ethanol extract on the 11th day, and gel with 5% betel nut ethanol extract on the 10th day. The results of One-way ANOVA statistical analysis showed a significant difference in the cuts healing effect of diabetic rabbits in each treatment with a value of p = 0.000 (p <0.05). Conclusion: The results of the study concluded that areca nut has activity in cuts healing in diabetic rabbits which was formulated in the form of a gel with an extract concentration of 5%.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44240990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review on Angiosarcoma of the Breast: Case Studies 乳腺血管肉瘤病例研究综述
Pub Date : 2023-03-22 DOI: 10.46610/jctr.2023.v05i01.003
Palvi Sharma, Vikrant Dalwal, Sunaina Rana, Shilpa Thakur, Anu Sharma
An uncommon kind of cancer called angiosarcoma originates in the lining of lymph and blood arteries. The immune system includes the lymphatic vessels. The lymph vessels remove waste materials, viruses, and germs from the body. Any region of the body can develop cancer of this kind. Angiosarcoma is an aggressive tumour, It is a form of soft tissue sarcoma. The treatment of angiosarcoma is very difficult. Breast cancer arises in the breast's lymphatic or blood vessel networks eventually migrating to the breast and the skin of the arms. Most angiosarcomas have unknown origins. Researchers have found a number of variables that could raise the disease's risk. Angiosarcoma develops when the DNA of cells lining a blood artery or lymph channel changes. The instructions that inform a cell what to do are encoded in its DNA. The adjustment which scientists refer to as mutations, instruct the cells to divide quickly. When healthy cells would perish, the alterations prevent the cells from dying. As a result, cancer cells can accumulate and spread outside of the blood vessel or lymph channel. Cancerous cells are able to infiltrate and obliterate healthy body tissue. Cancer cells could eventually separate and travel to different parts of the body. Angiosarcomas have a rapid development rate and body-wide dissemination. Breast angiosarcomas come in two varieties, primary and secondary, and they are both treated surgically by removing the tumour. Angiosarcoma can be spread in other part of body from breast. Primary breast angiosarcoma is an uncommon kind of breast cancer that only affects women, typically developing in the third to fourth decade. For diagnosis, biopsy, mammogram, breast MRI, PET Scan, ultrasound were performed and for the treatment of breast cancer surgery, chemotherapy, radiotherapy were performed. Only 0.04% of malignant breast tumours are primary breast angiosarcomas, making it a rare form of breast cancer. Secondary malignant tumour growth is one of the dangers of therapeutic radiation. In this paper, various cases are reported of angiosarcoma of the breast.
一种罕见的癌症称为血管肉瘤,起源于淋巴和血液动脉的内膜。免疫系统包括淋巴管。淋巴管清除体内的废物、病毒和细菌。身体的任何部位都可能发展成这种癌症。血管肉瘤是一种侵袭性肿瘤,是软组织肉瘤的一种。血管肉瘤的治疗非常困难。癌症发生在乳房的淋巴或血管网络中,最终转移到乳房和手臂的皮肤。大多数血管肉瘤起源不明。研究人员发现了许多可能增加疾病风险的变量。血管肉瘤是在血动脉或淋巴管内壁细胞的DNA发生变化时发展起来的。告知细胞该做什么的指令被编码在其DNA中。科学家们称之为突变的调整,指示细胞快速分裂。当健康细胞死亡时,这些变化会阻止细胞死亡。因此,癌症细胞可以积聚并扩散到血管或淋巴管外。癌细胞能够浸润和抹杀健康的身体组织。癌症细胞最终可能分离并传播到身体的不同部位。血管肉瘤的发展速度很快,并在全身范围内传播。乳腺血管肉瘤有两种,原发性和继发性,它们都是通过手术切除肿瘤来治疗的。血管肉瘤可以从乳房扩散到身体的其他部位。原发性乳腺血管肉瘤是一种罕见的癌症,只影响女性,通常在第三到第四个十年发展。进行诊断、活组织检查、乳房X光检查、乳腺MRI、PET扫描、超声检查,并进行癌症手术、化疗、放疗治疗。只有0.04%的恶性乳腺肿瘤是原发性乳腺血管肉瘤,这使其成为癌症的一种罕见形式。继发性恶性肿瘤生长是治疗性辐射的危险之一。本文报告了各种乳腺血管肉瘤的病例。
{"title":"A Review on Angiosarcoma of the Breast: Case Studies","authors":"Palvi Sharma, Vikrant Dalwal, Sunaina Rana, Shilpa Thakur, Anu Sharma","doi":"10.46610/jctr.2023.v05i01.003","DOIUrl":"https://doi.org/10.46610/jctr.2023.v05i01.003","url":null,"abstract":"An uncommon kind of cancer called angiosarcoma originates in the lining of lymph and blood arteries. The immune system includes the lymphatic vessels. The lymph vessels remove waste materials, viruses, and germs from the body. Any region of the body can develop cancer of this kind. Angiosarcoma is an aggressive tumour, It is a form of soft tissue sarcoma. The treatment of angiosarcoma is very difficult. Breast cancer arises in the breast's lymphatic or blood vessel networks eventually migrating to the breast and the skin of the arms. Most angiosarcomas have unknown origins. Researchers have found a number of variables that could raise the disease's risk. Angiosarcoma develops when the DNA of cells lining a blood artery or lymph channel changes. The instructions that inform a cell what to do are encoded in its DNA. The adjustment which scientists refer to as mutations, instruct the cells to divide quickly. When healthy cells would perish, the alterations prevent the cells from dying. As a result, cancer cells can accumulate and spread outside of the blood vessel or lymph channel. Cancerous cells are able to infiltrate and obliterate healthy body tissue. Cancer cells could eventually separate and travel to different parts of the body. Angiosarcomas have a rapid development rate and body-wide dissemination. Breast angiosarcomas come in two varieties, primary and secondary, and they are both treated surgically by removing the tumour. Angiosarcoma can be spread in other part of body from breast. Primary breast angiosarcoma is an uncommon kind of breast cancer that only affects women, typically developing in the third to fourth decade. For diagnosis, biopsy, mammogram, breast MRI, PET Scan, ultrasound were performed and for the treatment of breast cancer surgery, chemotherapy, radiotherapy were performed. Only 0.04% of malignant breast tumours are primary breast angiosarcomas, making it a rare form of breast cancer. Secondary malignant tumour growth is one of the dangers of therapeutic radiation. In this paper, various cases are reported of angiosarcoma of the breast.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46154855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional Optimization for Post-Spinal Surgery Recovery. 脊柱手术后恢复的营养优化。
Pub Date : 2023-01-01 Epub Date: 2023-02-24
Anjalika Chalamgari, Grace Hey, Akanksha Dave, Annika Liu, Aparna Nanduru, Brandon Lucke-Wold

Adequate nutritional intake is a key component of uncomplicated recovery from spinal surgery. Though much in the literature exists regarding its importance, specific dietary regimens for spinal surgery remain understudied, and little is available in compiling both preoperative and postoperative nutritional recommendations for patients. The complexity that may exist with these recommendations -- especially in the context of patients with diabetes or those who use substances -- has led in recent years to the development of protocols such as Enhanced Recovery After Surgery (ERAS), which gives providers a guideline upon which to base their nutritional counselling. More innovative regimens, such as the use of bioelectrical impedance analyses to assess nutritional status, have also emerged, resulting in a vast array of dietary recommendations and protocols for spinal surgery. In the following paper, we aim to compile a few of these guidelines, comparing various preoperative and postoperative nutritional strategies as well as making note of special considerations, like patients with diabetes or those who use substances. We also work to overview several such dietary "protocols" available in the literature, with a special focus on ERAS and more recent regimens like the Northwestern High-Risk Spine Protocol. We briefly mentioned preclinical work on novel nutritional recommendations as well. Ultimately, we hope to highlight the importance of nutrition in spinal surgery and address the need for greater cohesion of dietary strategies already in existence.

充足的营养摄入是脊柱手术后恢复的关键组成部分。尽管文献中有很多关于其重要性的内容,但脊柱手术的特定饮食方案仍然研究不足,在为患者编制术前和术后营养建议方面也很少。这些建议可能存在的复杂性——尤其是在糖尿病患者或使用药物的患者的情况下——导致了近年来诸如术后增强恢复(ERAS)等协议的发展,该协议为提供者提供了营养咨询的指导方针。更具创新性的方案也出现了,例如使用生物电阻抗分析来评估营养状况,从而产生了大量的脊柱手术饮食建议和方案。在下面的论文中,我们旨在汇编其中的一些指南,比较各种术前和术后营养策略,并注意特殊注意事项,如糖尿病患者或使用药物的患者。我们还概述了文献中的几种此类饮食“方案”,特别关注ERAS和最近的方案,如西北高风险脊柱方案。我们还简要地提到了关于新营养建议的临床前工作。最终,我们希望强调营养在脊柱外科手术中的重要性,并解决现有饮食策略更具凝聚力的需求。
{"title":"Nutritional Optimization for Post-Spinal Surgery Recovery.","authors":"Anjalika Chalamgari, Grace Hey, Akanksha Dave, Annika Liu, Aparna Nanduru, Brandon Lucke-Wold","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Adequate nutritional intake is a key component of uncomplicated recovery from spinal surgery. Though much in the literature exists regarding its importance, specific dietary regimens for spinal surgery remain understudied, and little is available in compiling both preoperative and postoperative nutritional recommendations for patients. The complexity that may exist with these recommendations -- especially in the context of patients with diabetes or those who use substances -- has led in recent years to the development of protocols such as Enhanced Recovery After Surgery (ERAS), which gives providers a guideline upon which to base their nutritional counselling. More innovative regimens, such as the use of bioelectrical impedance analyses to assess nutritional status, have also emerged, resulting in a vast array of dietary recommendations and protocols for spinal surgery. In the following paper, we aim to compile a few of these guidelines, comparing various preoperative and postoperative nutritional strategies as well as making note of special considerations, like patients with diabetes or those who use substances. We also work to overview several such dietary \"protocols\" available in the literature, with a special focus on ERAS and more recent regimens like the Northwestern High-Risk Spine Protocol. We briefly mentioned preclinical work on novel nutritional recommendations as well. Ultimately, we hope to highlight the importance of nutrition in spinal surgery and address the need for greater cohesion of dietary strategies already in existence.</p>","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"5 1","pages":"1-16"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vital Medications in the World According to Preliminary BCS Classification: Prognostication of Solubility and Permeability 世界上根据BCS初步分类的重要药物:溶解度和渗透性的预测
Pub Date : 2022-09-28 DOI: 10.46610/jctr.2022.v04i02.001
Kiran Dudhat
The Biopharmaceutical Classification System (BCS) has been used as a predictive method to evaluate potential formulation impacts on oral medication bioavailability in humans. The BCS can assist in the prediction of in vivo product performance and the construction of mechanistic models that enable formulation assessments through the generation of scenarios when used in conjunction with in vitro dissolution testing. The applicability of current human BCS standards has not yet been examined in dogs, which restricts its application in canine medication development. The BCS has had a significant impact on drug discovery, development, and regulation on a global scale and the BCS continues to receive much validation, discussion, and extension in the literature. Drug regulatory organizations from all across the world have fully deployed the BCS when establishing bioavailability/bio-equivalence requirements for the approval of oral drugs with instant release (IR). In this study, we examine the provisional BCS classification of the most popular medications sold worldwide and discuss the BCS scientific framework and its influence on regulatory exercise of oral medicinal products. Also mentioned is the Biopharmaceutical Drug Disposition Classification System and how it relates to the BCS.
生物制药分类系统(BCS)已被用作评估制剂对人类口服药物生物利用度的潜在影响的预测方法。BCS可以帮助预测体内产品性能和构建机制模型,当与体外溶出度测试结合使用时,可以通过生成场景来评估制剂。目前人类BCS标准的适用性尚未在犬类中进行检验,这限制了其在犬类药物开发中的应用。BCS在全球范围内对药物发现、开发和监管产生了重大影响,并且在文献中继续得到许多验证、讨论和扩展。世界各地的药品监管机构在制定口服即释药物批准的生物利用度/生物等效性要求时,已经全面部署了BCS。在本研究中,我们研究了全球最受欢迎的药物的临时BCS分类,并讨论了BCS的科学框架及其对口服药物监管的影响。还提到了生物制药药品处置分类系统及其与BCS的关系。
{"title":"Vital Medications in the World According to Preliminary BCS Classification: Prognostication of Solubility and Permeability","authors":"Kiran Dudhat","doi":"10.46610/jctr.2022.v04i02.001","DOIUrl":"https://doi.org/10.46610/jctr.2022.v04i02.001","url":null,"abstract":"The Biopharmaceutical Classification System (BCS) has been used as a predictive method to evaluate potential formulation impacts on oral medication bioavailability in humans. The BCS can assist in the prediction of in vivo product performance and the construction of mechanistic models that enable formulation assessments through the generation of scenarios when used in conjunction with in vitro dissolution testing. The applicability of current human BCS standards has not yet been examined in dogs, which restricts its application in canine medication development. The BCS has had a significant impact on drug discovery, development, and regulation on a global scale and the BCS continues to receive much validation, discussion, and extension in the literature. Drug regulatory organizations from all across the world have fully deployed the BCS when establishing bioavailability/bio-equivalence requirements for the approval of oral drugs with instant release (IR). In this study, we examine the provisional BCS classification of the most popular medications sold worldwide and discuss the BCS scientific framework and its influence on regulatory exercise of oral medicinal products. Also mentioned is the Biopharmaceutical Drug Disposition Classification System and how it relates to the BCS.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42597028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Management of Neurotrauma: When to Intervene. 神经创伤的外科治疗:何时介入。
Pub Date : 2022-07-01 Epub Date: 2022-10-07
Daisy Valle, Xuban Palau Villarreal, Caroline Lunny, Anjalika Chalamgari, Manahil Wajid, Arman Mahmood, Siya Buthani, Brandon Lucke-Wold

Neurotrauma, often defined as abrupt damage to the brain or spinal cord, is a substantial cause of mortality and morbidity that is widely recognized. As such, establishing an effective course of action is crucial to the enhancement of neurotrauma guidelines and patient outcomes in healthcare worldwide. Following the onset of neurotraumatic injuries, time is perhaps the most critical facet in diminishing mortality and morbidity rates. Thus, procuring the airway should be of utmost priority in a patient to allow for optimal ventilation, with a shift in focus resorting to surgical interventions after the patient reaches a suitable care facility. In particular, ventriculoperitoneal shunt (VPS) procedures have long been utilized to treat traumatic brain and spinal cord injuries to direct additional cerebrospinal fluid (CSF) from the lateral ventricles through a ventricular catheter attached to a valve that is further connected to a distal catheter. Decompressive cranio omie (DCs), cranioplasties, and intracranial pressure measurements (ICP) are also frequently performed in combination with VPS to manage intracranial hypertension and cerebral edema. Although the current surgical methods utilized in the treatment of neurotrauma prove to be highly efficacious in the prevention of adverse outcomes, emergent therapies are growing in popularity. Of interest, the Three Pillars Expansive Craniotomy, cisternostomy, and external lumbar drainages are cutting-edge procedures with promising results that can potentially usher change in the neurosurgical industry but require additional examination.

神经创伤通常被定义为大脑或脊髓的突然损伤,是死亡和发病率的重要原因,这一点得到了广泛认可。因此,制定有效的行动方案对于加强神经创伤指南和全球医疗保健中的患者结果至关重要。神经创伤发作后,时间可能是降低死亡率和发病率的最关键因素。因此,获取气道应该是患者的首要任务,以实现最佳通气,在患者到达合适的护理机构后,重点转移到外科干预。特别地,脑室-腹腔分流术(VPS)程序长期以来一直被用于治疗创伤性脑损伤和脊髓损伤,以通过连接到进一步连接到远端导管的瓣膜的心室导管从侧脑室引导额外的脑脊液(CSF)。减压开颅术(DC)、开颅术和颅内压测量(ICP)也经常与VPS联合进行,以治疗颅内高压和脑水肿。尽管目前用于治疗神经创伤的手术方法被证明在预防不良后果方面非常有效,但紧急疗法越来越受欢迎。令人感兴趣的是,三支柱扩张性颅骨切除术、脑池切除术和腰椎外引流术是尖端的手术,具有良好的效果,可能会给神经外科行业带来变革,但需要额外的检查。
{"title":"Surgical Management of Neurotrauma: When to Intervene.","authors":"Daisy Valle, Xuban Palau Villarreal, Caroline Lunny, Anjalika Chalamgari, Manahil Wajid, Arman Mahmood, Siya Buthani, Brandon Lucke-Wold","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neurotrauma, often defined as abrupt damage to the brain or spinal cord, is a substantial cause of mortality and morbidity that is widely recognized. As such, establishing an effective course of action is crucial to the enhancement of neurotrauma guidelines and patient outcomes in healthcare worldwide. Following the onset of neurotraumatic injuries, time is perhaps the most critical facet in diminishing mortality and morbidity rates. Thus, procuring the airway should be of utmost priority in a patient to allow for optimal ventilation, with a shift in focus resorting to surgical interventions after the patient reaches a suitable care facility. In particular, ventriculoperitoneal shunt (VPS) procedures have long been utilized to treat traumatic brain and spinal cord injuries to direct additional cerebrospinal fluid (CSF) from the lateral ventricles through a ventricular catheter attached to a valve that is further connected to a distal catheter. Decompressive cranio omie (DCs), cranioplasties, and intracranial pressure measurements (ICP) are also frequently performed in combination with VPS to manage intracranial hypertension and cerebral edema. Although the current surgical methods utilized in the treatment of neurotrauma prove to be highly efficacious in the prevention of adverse outcomes, emergent therapies are growing in popularity. Of interest, the Three Pillars Expansive Craniotomy, cisternostomy, and external lumbar drainages are cutting-edge procedures with promising results that can potentially usher change in the neurosurgical industry but require additional examination.</p>","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"4 2","pages":"41-55"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9211591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Application of Tocilizumab in Covid-19 Patients 托珠单抗在Covid-19患者中的临床应用
Pub Date : 2022-02-07 DOI: 10.46610/jctr.2022.v04i01.001
Pranjal Chandrakar, Hemasri Velmurugan, P. T, D. Dash, Vaibhav Tripathi
Over these previous years, clinicians dealing with patients with COVID infection 2019 have discovered that the abundant inflammatory response induced by the virus serves as a significant cause of the acute respiratory distress syndrome (ARDS) and multi-organ dysfunction, which happen in majority of the lethal cases. Presently, there is not a single drug available as an approved and genuine medication for corona infection, in this sphere of time immunomodulatory agents has exhibited encouraging response against coronavirus infection. The initial finding that interleukin-6 (IL-6) levels are raised in serious COVID-19 and independently foresee the risk of developing ARDS and finally death, such results had centered the clinical investigations on this pro-incendiary and pleiotropic cytokine. Tocilizumab (TCZ) is humanized anti-interleukin 6 receptor monoclonal immunizer and has been endorsed for different rheumatological ailments. Currently, many steroids as they act as an immunomodulatory agent have shown fantastic therapeutic effects while used in COVID infected peoples, such clinical data advocated the application of tocilizumab to combat corona infection. Patients who were in life threatening condition because of COVID-19 initiated pneumonia developed hyper aggravation. This medication lessens the further decay of the patient caused because of agglomeration of lymphocytic cells and diminishes the degree of high CRP (C-responsive protein). Nevertheless, several clinical investigations have been in progress to ascertain the drug profile. So that TCZ may be used in COVID patients with optimal effectiveness associated with minimum risk of adverse events. In this article, we have tried to encompass all relevant information about the pharmacology of TCZ, which will surely help to understand clinical behaviour of the drug.
在过去的几年里,与2019冠状病毒感染患者打交道的临床医生发现,病毒诱导的大量炎症反应是导致急性呼吸窘迫综合征(ARDS)和多器官功能障碍的重要原因,这在大多数致命病例中都会发生。目前,还没有一种药物被批准为治疗冠状病毒感染的真正药物,在这段时间里,免疫调节剂对冠状病毒感染表现出令人鼓舞的反应。最初发现白细胞介素-6 (IL-6)水平在严重的COVID-19中升高,并独立预测发生ARDS和最终死亡的风险,这些结果使临床研究集中在这种具有促燃烧性和多效性的细胞因子上。Tocilizumab (TCZ)是一种人源化抗白细胞介素6受体单克隆免疫剂,已被批准用于不同的风湿病。目前,许多类固醇作为免疫调节剂在COVID - 19感染者中使用时显示出良好的治疗效果,这些临床数据提倡使用托珠单抗来对抗冠状病毒感染。因COVID-19引发的肺炎而处于生命危险状态的患者出现了严重加重。这种药物减少了由于淋巴细胞聚集引起的患者的进一步衰退,并降低了高CRP (c反应蛋白)的程度。尽管如此,一些临床研究正在进行中,以确定药物的特征。因此,TCZ可以以最佳的疗效和最小的不良事件风险用于COVID患者。在这篇文章中,我们试图包含有关TCZ药理学的所有相关信息,这必将有助于了解药物的临床行为。
{"title":"Clinical Application of Tocilizumab in Covid-19 Patients","authors":"Pranjal Chandrakar, Hemasri Velmurugan, P. T, D. Dash, Vaibhav Tripathi","doi":"10.46610/jctr.2022.v04i01.001","DOIUrl":"https://doi.org/10.46610/jctr.2022.v04i01.001","url":null,"abstract":"Over these previous years, clinicians dealing with patients with COVID infection 2019 have discovered that the abundant inflammatory response induced by the virus serves as a significant cause of the acute respiratory distress syndrome (ARDS) and multi-organ dysfunction, which happen in majority of the lethal cases. Presently, there is not a single drug available as an approved and genuine medication for corona infection, in this sphere of time immunomodulatory agents has exhibited encouraging response against coronavirus infection. The initial finding that interleukin-6 (IL-6) levels are raised in serious COVID-19 and independently foresee the risk of developing ARDS and finally death, such results had centered the clinical investigations on this pro-incendiary and pleiotropic cytokine. Tocilizumab (TCZ) is humanized anti-interleukin 6 receptor monoclonal immunizer and has been endorsed for different rheumatological ailments. Currently, many steroids as they act as an immunomodulatory agent have shown fantastic therapeutic effects while used in COVID infected peoples, such clinical data advocated the application of tocilizumab to combat corona infection. Patients who were in life threatening condition because of COVID-19 initiated pneumonia developed hyper aggravation. This medication lessens the further decay of the patient caused because of agglomeration of lymphocytic cells and diminishes the degree of high CRP (C-responsive protein). Nevertheless, several clinical investigations have been in progress to ascertain the drug profile. So that TCZ may be used in COVID patients with optimal effectiveness associated with minimum risk of adverse events. In this article, we have tried to encompass all relevant information about the pharmacology of TCZ, which will surely help to understand clinical behaviour of the drug.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70565668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmaceutical Law and Patent Law 制药法与专利法
Pub Date : 2021-11-16 DOI: 10.46610/jctr.2021.v03i02.005
Carlo A. Piria
The patent law and pharma laws and regulations need to be coordinated. The interpretative proposal of the author is that a patent claim aiming at protecting the invention as a medicinal product must necessarily be expressed using the appropriate terms provided for by the laws and regulations concerning the industrial medicinal product, such as “medicinal product” and “active substance”; otherwise the patent may not be considered as covering a “medicinal product” or an “active substance”. Moreover, as a consequence, the presentation of a product in a patent claim as a medicinal product or an active substance implies that the enforceability of such claim is conditioned upon the demonstration of the efficacy and safety of the product through the preparation and approval by the competent authorities of a dossier of pharmacological and clinical trials. The legal system taken into consideration by the author is the European one, but the interpretative proposal is, mutatis mutandis, applicable to other systems of law.
专利法和制药法律法规需要协调。提交人的解释性建议是,旨在保护作为医药产品的发明的专利权利要求必须使用有关工业医药产品的法律法规规定的适当术语来表达,如“医药产品”和“活性物质”;否则,该专利可能不被视为涵盖“医药产品”或“活性物质”。此外,因此,专利权利要求中的产品作为医药产品或活性物质的陈述意味着,该权利要求的可执行性取决于通过主管当局制备和批准药理学和临床试验档案来证明该产品的有效性和安全性。提交人所考虑的法律制度是欧洲的法律制度,但该解释性建议经必要修改后适用于其他法律制度。
{"title":"Pharmaceutical Law and Patent Law","authors":"Carlo A. Piria","doi":"10.46610/jctr.2021.v03i02.005","DOIUrl":"https://doi.org/10.46610/jctr.2021.v03i02.005","url":null,"abstract":"The patent law and pharma laws and regulations need to be coordinated. The interpretative proposal of the author is that a patent claim aiming at protecting the invention as a medicinal product must necessarily be expressed using the appropriate terms provided for by the laws and regulations concerning the industrial medicinal product, such as “medicinal product” and “active substance”; otherwise the patent may not be considered as covering a “medicinal product” or an “active substance”. Moreover, as a consequence, the presentation of a product in a patent claim as a medicinal product or an active substance implies that the enforceability of such claim is conditioned upon the demonstration of the efficacy and safety of the product through the preparation and approval by the competent authorities of a dossier of pharmacological and clinical trials. The legal system taken into consideration by the author is the European one, but the interpretative proposal is, mutatis mutandis, applicable to other systems of law.","PeriodicalId":73671,"journal":{"name":"Journal of clinical trials and regulations","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41365763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of clinical trials and regulations
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1